Efficacy of Chatbot for Irritable Bowel Syndrome (IBS) Patients

Launched by RESEARCH AND PRACTICAL CLINICAL CENTER FOR DIAGNOSTICS AND TELEMEDICINE TECHNOLOGIES OF THE MOSCOW HEALTH CARE DEPARTMENT · Feb 14, 2025

Keywords

ClinConnect Summary

The study consists of three stages:

Stage 1: Patients with Irritable Bowel Syndrome (IBS) who meet the eligibility criteria will be invited to participate in the study. After providing written informed consent, all participants will be asked to complete a set of questionnaires to assess various parameters:

1. Irritable Bowel Syndrome Quality of Life (IBS-QOL);
2. Quality of Life - Short Form-36 (SF-36);
3. Symptoms of Anxiety and/or Depression - Hospital Anxiety and Depression Scale (HADS);
4. State and Trait Anxiety Levels - State-Trait Anxiety Inventory (STAI);
5. Visceral Sensitivity -...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults ≥18 years;
• • Diagnosed with IBS;
• • Signed informed consent.
• Exclusion Criteria:
• • Age under 18 years;
• • Pregnant individuals;
• • Patients with cognitive or sensory impairments that hinder understanding of questions in surveys, scales, or instruments used in the study;
• • Patients unable to use a chatbot;
• • Patients currently participating in any other clinical trial or experimental study;
• • Patients with psychotic symptoms;
• • Patients with other conditions that may influence the endpoints of the current study.